Triple Threat-Triple Benefit: The Rise of GLP1-GCG-FGF21 Tritagonists in Tomorrow’s Metabolic Medicine . d [Internet]. 2025 Dec. 1 [cited 2026 Apr. 14];3(3):43-8. Available from: https://www.thediabzen.com/index.php/d/article/view/19